carmofur has been researched along with Colorectal Neoplasms in 22 studies
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 9.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area." | 9.10 | [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002) |
| "A multi-institutional study was performed to evaluate the appropriate duration of oral administration of Carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative operation." | 9.09 | Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. ( Fujii, H; Kamigaki, T; Kuroda, Y; Nakamura, T; Ohno, M; Tabuchi, Y; Yamagishi, H, 2001) |
| "A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection." | 9.08 | Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "We studied the effect of postoperative chemotherapy using 5-fluorouracil (5-FU) infusions and 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration for curatively resected Stage II to IV colorectal cancer." | 9.08 | Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996) |
| "A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection." | 9.08 | Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. ( Baba, S; Ishii, M; Ito, K; Kato, T; Matsumoto, S; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 5.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area." | 5.10 | [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002) |
| "A multi-institutional study was performed to evaluate the appropriate duration of oral administration of Carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative operation." | 5.09 | Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. ( Fujii, H; Kamigaki, T; Kuroda, Y; Nakamura, T; Ohno, M; Tabuchi, Y; Yamagishi, H, 2001) |
| "A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection." | 5.08 | Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "We studied the effect of postoperative chemotherapy using 5-fluorouracil (5-FU) infusions and 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration for curatively resected Stage II to IV colorectal cancer." | 5.08 | Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996) |
| "A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection." | 5.08 | Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. ( Baba, S; Ishii, M; Ito, K; Kato, T; Matsumoto, S; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "A joint multicenter comparative study of carmofur (HCFU) alone or HCFU+dipyridamole (DP) concurrent administration was conducted by the Kinki Colorectal Cancer Chemotherapy Society." | 5.07 | [Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]. ( Fukuda, I; Hioki, K; Imaoka, S; Kameyama, M; Kikkawa, N; Mori, T; Nakamori, S; Oshima, A; Utsunomiya, J; Yasutomi, M, 1993) |
| "In Western countries, efficacy of 5-fluorouracil (5-FU)+leucovorin (LV) as adjuvant chemotherapy for colorectal cancer has been already established." | 4.83 | [Adjuvant chemotherapy for colorectal cancer]. ( Akasu, T, 2006) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Of them, 315 node-negative stage II colorectal cancer cases were enrolled." | 1.43 | Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. ( Doki, Y; Fukunaga, M; Ikeda, M; Kato, T; Matsuura, N; Miyake, Y; Mizushima, T; Monden, M; Mori, M; Murata, K; Nakamura, Y; Nezu, R; Noura, S; Ohnishi, T; Ohtsuka, M; Ohue, M; Sekimoto, M; Takemasa, I; Yamamoto, H, 2016) |
| " Preoperative regimens of HCFU 240 mg/m2/day, given by 14-day oral dosage or HCFU 240 mg/m2/day and DP (Dipyridamole) 300 mg/body/day, both 14-day oral dosage were used." | 1.29 | [TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator]. ( Sakuyama, T; Takahashi, N, 1994) |
| "The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations." | 1.28 | [Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 9 (40.91) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hermunen, K | 2 |
| Lantto, E | 1 |
| Poussa, T | 1 |
| Haglund, C | 2 |
| Österlund, P | 4 |
| Yamamoto, H | 1 |
| Murata, K | 1 |
| Fukunaga, M | 1 |
| Ohnishi, T | 1 |
| Noura, S | 1 |
| Miyake, Y | 1 |
| Kato, T | 3 |
| Ohtsuka, M | 1 |
| Nakamura, Y | 1 |
| Takemasa, I | 1 |
| Mizushima, T | 1 |
| Ikeda, M | 1 |
| Ohue, M | 1 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Matsuura, N | 1 |
| Monden, M | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Sakai, T | 1 |
| Yamashita, Y | 1 |
| Maekawa, T | 1 |
| Mikami, K | 1 |
| Hoshino, S | 1 |
| Shirakusa, T | 1 |
| Orpana, A | 1 |
| Elomaa, I | 2 |
| Repo, H | 1 |
| Joensuu, H | 2 |
| Kotake, K | 2 |
| Koyama, Y | 2 |
| Shida, S | 1 |
| Tajima, Y | 1 |
| Ishikawa, H | 1 |
| Kanazawa, K | 1 |
| Miyata, M | 1 |
| Nagamachi, Y | 1 |
| Iwasaki, Y | 1 |
| Omoto, R | 1 |
| Tamakuma, S | 1 |
| Kitajima, M | 1 |
| Kodaira, S | 2 |
| Ohashi, Y | 1 |
| Akasu, T | 1 |
| Sakuyama, T | 1 |
| Takahashi, N | 1 |
| Kameyama, M | 2 |
| Nakamori, S | 1 |
| Imaoka, S | 1 |
| Utsunomiya, J | 2 |
| Oshima, A | 2 |
| Kikkawa, N | 2 |
| Hioki, K | 2 |
| Fukuda, I | 2 |
| Mori, T | 2 |
| Yasutomi, M | 2 |
| Ito, K | 2 |
| Yamaguchi, A | 2 |
| Miura, K | 2 |
| Koike, A | 1 |
| Takagi, H | 2 |
| Sugimachi, K | 1 |
| Maehara, Y | 1 |
| Ogawa, M | 1 |
| Kakegawa, T | 1 |
| Tomita, M | 1 |
| Akiyoshi, T | 1 |
| Kanno, H | 1 |
| Yoden, Y | 1 |
| Ohashi, S | 1 |
| Iwanaga, T | 1 |
| Baba, S | 1 |
| Matsumoto, S | 1 |
| Ishii, M | 1 |
| Sasaki, K | 1 |
| Takasaka, H | 1 |
| Kawasaki, H | 1 |
| Matsunaga, T | 1 |
| Nakagawa, N | 1 |
| Shibata, K | 1 |
| Yabana, T | 1 |
| Yasojima, T | 1 |
| Furuhata, T | 1 |
| Hata, F | 1 |
| Hirata, K | 1 |
| Nakamura, T | 1 |
| Ohno, M | 1 |
| Tabuchi, Y | 1 |
| Kamigaki, T | 1 |
| Fujii, H | 1 |
| Yamagishi, H | 1 |
| Kuroda, Y | 1 |
| Virkkunen, P | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Tohnosu, N | 1 |
| Koide, Y | 1 |
| Matsubara, H | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Matsushita, K | 1 |
| Amano, H | 1 |
| Ochiai, T | 1 |
| Moriya, Y | 1 |
| Sugihara, K | 1 |
| Hojo, K | 1 |
| Makuuchi, M | 1 |
| Tsuji, Y | 1 |
| Nishimura, A | 1 |
| Katsuki, Y | 1 |
| Yasuda, T | 1 |
| Nishiyama, M | 1 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Saeki, T | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
1 review available for carmofur and Colorectal Neoplasms
| Article | Year |
|---|---|
[Adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug C | 2006 |
10 trials available for carmofur and Colorectal Neoplasms
| Article | Year |
|---|---|
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Ca | 2018 |
[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 2002 |
A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2005 |
[Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Dipyridamole; Female; Fluorouracil; Humans | 1993 |
Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1996 |
Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1996 |
[Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma--TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dru | 1996 |
Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplas | 1996 |
Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplas | 2001 |
[Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma. (Second report): 5-year survival rate. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1989 |
11 other studies available for carmofur and Colorectal Neoplasms
| Article | Year |
|---|---|
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Dise | 2016 |
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2008 |
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil | 2013 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator].
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dipyridamole; DNA, | 1994 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr | 2000 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne | 1990 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |